This invention provides a composite
adjuvant, its preparation method, and its application in vaccine preparation, belonging to the field of
vaccine adjuvant technology. The composite
adjuvant of this invention has low
viscosity, only 12 mPa·s at 20°C, ensuring smooth injection; it exhibits high
biocompatibility, with no deaths or organ abnormalities in
acute toxicity experiments in mice, and no local or systemic adverse reactions or stress responses in chickens after injection; it also demonstrates excellent
immunogenicity, achieving a 90% seroconversion rate for
Mycoplasma cambogia and an 80% seroconversion rate for
Mycoplasma synoviae 28 days after immunization with an inactivated
Mycoplasma synoviae vaccine.